Renal Cell Carcinoma Clinical Trials

218 recruitingLast updated: June 17, 2026

There are 218 actively recruiting renal cell carcinoma clinical trials across 40 countries. Studies span Phase 2, Phase 1, Not Applicable, Phase 3, Early Phase 1, Phase 4. Top locations include Houston, Texas, United States, New York, New York, United States, Dallas, Texas, United States. Updated daily from ClinicalTrials.gov.


Renal Cell Carcinoma Trials at a Glance

218 actively recruiting trials for renal cell carcinoma are listed on ClinicalTrialsFinder across 6 cities in 40 countries. The largest study group is Phase 2 with 91 trials, with the heaviest enrollment activity in Houston, New York, and Dallas. Lead sponsors running renal cell carcinoma studies include M.D. Anderson Cancer Center, Mayo Clinic, and National Cancer Institute (NCI).

Browse renal cell carcinoma trials by phase

Treatments under study

About Renal Cell Carcinoma Clinical Trials

Looking for clinical trials for Renal Cell Carcinoma? There are currently 99 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Renal Cell Carcinoma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Renal Cell Carcinoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 218 trials

Recruiting
Phase 2

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

Stage IV Renal Cell Cancer AJCC v8Stage IVB Prostate Cancer AJCC v8Large Cell Neuroendocrine Carcinoma+42 more
National Cancer Institute (NCI)314 enrolled578 locationsNCT03866382
Recruiting
Not Applicable

Investigation of Lymph Node Biology in Kidney Cancer

Renal Cell Carcinoma (RCC)
Yale University33 enrolled1 locationNCT07038733
Recruiting
Phase 2

An Investigational Scan (89Zr-DFO-GmAb PET/CT) Compared to Contrast-Enhanced CT for the Detection of Recurrent Clear Cell Renal Cell Cancer After Surgery Comparing Carbonic Anhydrase IX (CAIX) PET CT to Conventional PET CT for Post-Op Staging in Kidney Cancer

Clear Cell Renal Cell CarcinomaSarcomatoid Renal Cell CarcinomaStage III Renal Cell Cancer+2 more
Jonsson Comprehensive Cancer Center91 enrolled1 locationNCT06447103
Recruiting
Phase 3

A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)

Renal Cell Carcinoma
Merck Sharp & Dohme LLC904 enrolled111 locationsNCT07227402
Recruiting
Phase 4

Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study

Metastatic Head and Neck Squamous Cell CarcinomaMetastatic Hepatocellular CarcinomaMetastatic Lung Non-Small Cell Carcinoma+18 more
OHSU Knight Cancer Institute160 enrolled1 locationNCT07405086
Recruiting
Phase 2

Phase II Trial of Single Agent Belzutifan or Pembrolizumab Versus Combination as Neoadjuvant Therapy in Clear Cell Renal Cell Carcinoma (BLAZE)

Clear Cell Renal Cell Carcinoma
M.D. Anderson Cancer Center10 enrolled1 locationNCT07187778
Recruiting
Phase 1Phase 2

A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors

Triple-Negative Breast CancerMelanomaNon-small Cell Lung Cancer+6 more
AstraZeneca60 enrolled13 locationsNCT07115043
Recruiting
Phase 1

Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma

Clear Cell Renal Cell Carcinoma
Xencor, Inc.307 enrolled26 locationsNCT05433142
Recruiting
Early Phase 1

The Safety and Efficacy of Allogeneic CD70 CAR-T Therapy in Unresectable or Metastatic Clear Cell Renal Cell Carcinoma

Unresectable or Metastatic Clear Cell Renal Cell Carcinoma
Chinese PLA General Hospital30 enrolled3 locationsNCT07645690
Recruiting
Phase 3

Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer

Stage III Renal Cell Cancer AJCC v8Stage IV Renal Cell Cancer AJCC v8Metastatic Clear Cell Renal Cell Carcinoma+1 more
SWOG Cancer Research Network718 enrolled41 locationsNCT07383441
Recruiting
Phase 1

A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)

Renal Cell Carcinoma
Bristol-Myers Squibb125 enrolled9 locationsNCT07195682
Recruiting
Phase 2

Ivonescimab Prior to Surgery for the Treatment of High-Risk Localized Clear Cell Renal Cell Cancer

Stage III Renal Cell Cancer AJCC v8Stage IV Renal Cell Cancer AJCC v8Stage II Renal Cell Cancer AJCC v8+2 more
City of Hope Medical Center31 enrolled1 locationNCT07226544
Recruiting
Phase 2

Adding a Live Biotherapeutic Product (CBM588) to Pembrolizumab for the Treatment of Renal Cell Cancer After Surgery

Stage III Renal Cell Cancer AJCC v8Stage IV Renal Cell Cancer AJCC v8Clear Cell Renal Cell Carcinoma+2 more
City of Hope Medical Center62 enrolled2 locationsNCT07037004
Recruiting
Phase 2

Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program

Urothelial CarcinomaEsophageal CarcinomaHepatocellular Carcinoma+28 more
Mayo Clinic50 enrolled1 locationNCT06265285
Recruiting
Phase 4

Digital Monitoring of Self-reported Symptoms by Patients Treated With Cabozantinib Plus Nivolumab for Advanced Clear-cell Renal Carcinoma

Metastatic Renal Cell CarcinomaLocally AdvancedRenal Cell Carcinoma (Kidney Cancer)
Centre Francois Baclesse83 enrolled16 locationsNCT07028125
Recruiting
Phase 1

GCAR1, a Chimeric Antigen Receptor (CAR) T-CELL Therapy for Relapsed/Refractory GPNMB-Expressing Solid Tumours

Triple-Negative Breast CancerRenal Cell CarcinomaAlveolar Soft Part Sarcoma
Canadian Cancer Trials Group30 enrolled1 locationNCT07297667
Recruiting
Phase 1

KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors

Non-small Cell Lung Cancer (NSCLC)Pancreatic Ductal Adenocarcinoma (PDAC)Colorectal Cancer (CRC)+4 more
Kura Oncology, Inc.300 enrolled38 locationsNCT06026410
Recruiting
Phase 1

A Phase 1 Study of the Safety and Tolerability of CTX-10726

Endometrial CancerRenal Cell Carcinoma (RCC)Hepatocellular Carcinoma (HCC)+1 more
Compass Therapeutics70 enrolled5 locationsNCT07419841
Recruiting
Not Applicable

ClAmpless, Sutureless PartIAl Nephrectomy for Renal Masses

Renal Cell Carcinoma (RCC)
University of Florida59 enrolled1 locationNCT06722807
Recruiting

Role of TTV During First-line Immunotherapy Treatment in Patients With Renal Cell Carcinoma

Renal Cell Carcinoma
Regina Elena Cancer Institute20 enrolled1 locationNCT07018037